Immatics Biotechnologies GmbH announced the appointment of Cedrik Britten, MD, as Chief Medical Officer (CMO) effective June 1, 2020. Trained as a physician, Cedrik Britten will join the company with more than a decade of experience in clinical development including his most recent position as Vice President and Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline. He will be responsible for the management and global development of the company’s clinical pipeline. In parallel, Carsten Reinhardt, MD, PhD, the current Chief Medical Officer at the company, will assume the newly created role as Chief Development Officer to lead company’ product development strategy. Carsten will also continue to lead the TCR Bispecifics platform and pipeline and the Immunology and Translational Development functions at the company. Stephen Eck, MD, PhD, the current Chief Medical Officer at Immatics US in Houston (TX), will step down and remain with the Company until the end of June to support the transition. Cedrik Britten, MD, brings over ten years of experience in clinical and preclinical research as well as drug development in the field of immuno-oncology. He most recently served as Vice President and Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline in the United Kingdom, where he was responsible for the early cell therapy pipeline in Oncology R&D which included clinical development to proof-of-concept. In this role, he also established research and development teams and led the development of TCR-T as well as early-stage CAR-T programs. Prior to that, he held various senior positions at BioNTech including Vice President for R&D. During his time at BioNTech, he built and established clinical research teams, was responsible for early drug development and led clinical, as well as non-clinical, oncology development programs for personalized cancer immunotherapy products. Cedrik Britten graduated from the Johannes Gutenberg-University in Mainz, Germany, with both a medical and doctoral degree.